Identification of Interleukin1β as an Amplifier of Interferon alpha-induced Antiviral Responses

PLoS Pathog. 2020 Oct 1;16(10):e1008461. doi: 10.1371/journal.ppat.1008461. eCollection 2020 Oct.

Abstract

The induction of an interferon-mediated response is the first line of defense against pathogens such as viruses. Yet, the dynamics and extent of interferon alpha (IFNα)-induced antiviral genes vary remarkably and comprise three expression clusters: early, intermediate and late. By mathematical modeling based on time-resolved quantitative data, we identified mRNA stability as well as a negative regulatory loop as key mechanisms endogenously controlling the expression dynamics of IFNα-induced antiviral genes in hepatocytes. Guided by the mathematical model, we uncovered that this regulatory loop is mediated by the transcription factor IRF2 and showed that knock-down of IRF2 results in enhanced expression of early, intermediate and late IFNα-induced antiviral genes. Co-stimulation experiments with different pro-inflammatory cytokines revealed that this amplified expression dynamics of the early, intermediate and late IFNα-induced antiviral genes can also be achieved by co-application of IFNα and interleukin1 beta (IL1β). Consistently, we found that IL1β enhances IFNα-mediated repression of viral replication. Conversely, we observed that in IL1β receptor knock-out mice replication of viruses sensitive to IFNα is increased. Thus, IL1β is capable to potentiate IFNα-induced antiviral responses and could be exploited to improve antiviral therapies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology
  • Gene Expression Regulation, Viral / drug effects*
  • Hepatocytes / cytology
  • Hepatocytes / drug effects
  • Hepatocytes / immunology
  • Hepatocytes / virology
  • Humans
  • Interferon Regulatory Factor-2 / genetics
  • Interferon Regulatory Factor-2 / metabolism*
  • Interferon-alpha / pharmacology*
  • Lymphocytic Choriomeningitis / drug therapy*
  • Lymphocytic Choriomeningitis / immunology
  • Lymphocytic Choriomeningitis / pathology
  • Lymphocytic Choriomeningitis / virology
  • Lymphocytic choriomeningitis virus / drug effects*
  • Lymphocytic choriomeningitis virus / isolation & purification
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • RNA Stability
  • Receptors, Interleukin-1 Type I / physiology*
  • Virus Replication / drug effects*

Substances

  • Antiviral Agents
  • IL1R1 protein, mouse
  • Interferon Regulatory Factor-2
  • Interferon-alpha
  • Receptors, Interleukin-1 Type I

Grants and funding

Funding: This study was funded by the German Ministry for Education (BMBF) (https://www.bmbf.de/) within the grants FORSYS initiative ViroQuant (0313923 to AS, TM, RB, UK), the e:Bio network ImmunoQuant (0316170B to KR, UK; 0316170C to JW, MBi, RB), the Virtual Liver Network (0315745 to XH, UK; 0315766 to JT, CK; 0315713 to JGB; 0315741 to GD, DS), the EraSysAPP consortium IMOMESIC (031A604A to UK; 031A604B JT; 031A604C to GD, DS) and by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) (https://www.dfg.de/) – Projektnummer 272983813 – TRR 179 (to RB, UK, MT, JT, MBi), Projektnummer 190586431 - SFB 974 (to PAL, JGB) and Projektnummer 231604701 - GRK 1949 (to PAL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.